Oxford, UK – 16 June 2025: OXB has been ranked 34th out of 300 organisations in Fortune’s list of Europe’s most innovative companies, a recognition that underscores the company’s leadership in cell and gene therapy innovation. The list, compiled based on evaluations by industry experts and employees, highlights businesses delivering… Read More
Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK The Company remains on track to deliver the outlook set out in the Preliminary Results published on 9 April 2025 Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell… Read More
Oxford, UK – 03 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board (ITEB). The ITEB brings together leading experts in cell and gene therapy, scientific innovation, and advanced manufacturing. It will… Read More
Oxford, UK – 8 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from 13–17 May 2025 at the Ernest N. Morial Convention Center… Read More
Oxford, UK – 28 April 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the 2024 Annual report and accounts are being sent to shareholders today. These documents are available on… Read More
Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1 Operating EBITDA2 loss of £(15.3) million for the full year in line with expectations, Operating EBITDA profit of £5.0 million achieved in second half of 2024 Contracted… Read More
Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the “Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the ‘Cell & Gene Therapy – Global’ category at the 2025 CDMO Leadership Awards. The annual CDMO Leadership Awards… Read More
Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at… Read More
Oxford, UK – 20 February 2025: OXB (LSE:OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR™ 1 trial. The Phase I/II study is evaluating BI 3720931, a novel, first-in-class, inhaled… Read More
Oxford, UK – 17 February 2025: OXB (LSE:OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today provides a trading update for the full year ended 31 December 2024. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “We are continuing to execute our multi-vector, multi-site “One… Read More
Oxford, UK – 20 November 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products. The webinar titled “Accelerating Viral Vector… Read More
Oxford, UK – 18 November 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Colin Bond as a Non-Executive Director effective 1 January 2025. Mr. Bond will also join the Audit Committee as part of succession planning ahead of Stuart Henderson losing his… Read More